DRRX / DURECT Corporation - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company)

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company) DURECT CORPORATION (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 266605500 (CUS

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

EX-99.(A)(5)(B) Exhibit (a)(5)(B) Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] 877-281-6642 (toll-free) (908) 569-3692 Investor Relations (DURECT Corporation) Media Contact (DURECT Corporation) Sandya von der Weid Michael Fitzhugh LifeSci Advisors LifeSci Communications [email protected] mfitzhugh@lifesc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (

Offer to Purchase All Outstanding Shares of Common Stock DURECT CORPORATION $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, o

EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of DURECT CORPORATION at $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, upon the achievement of specified milestones

Offer to Purchase All Outstanding Shares of Common Stock DURECT CORPORATION $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, o

EX-99.(a)(1)(E) Exhibit (a)(1)(E) Offer to Purchase All Outstanding Shares of Common Stock of DURECT CORPORATION at $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, upon the achievement of specified milestones

Letter of Transmittal to Tender Shares of Common Stock DURECT CORPORATION $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of

EX-99.(a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of DURECT CORPORATION at $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, upon the achievement of specified milestones (m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company) DURECT CORPORATION

SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Notice of Guaranteed Delivery Offer to Purchase All Outstanding Shares of Common Stock DURECT CORPORATION $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive th

EX-99.(a)(1)(C) Exhibit (a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase All Outstanding Shares of Common Stock of DURECT CORPORATION at $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, upon the ac

Offer to Purchase All Outstanding Shares of Common Stock DURECT CORPORATION $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, o

EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of DURECT CORPORATION at $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, upon the achievement of specified milestones

Calculation of Filing Fee Tables SCHEDULE TO (Rule 14d-100) DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMPANIES

Exhibit 107 Calculation of Filing Fee Tables SCHEDULE TO (Rule 14d-100) DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON

SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMPANIES INC. (Names of

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by

EX-99.(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by the Offer to Purchase, dated as of August 12, 2025, and the related Letter of Transmittal and any amendments or sup

DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones Transaction expected to close i

Exhibit 99.1 DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones Transaction expected to close in the third quarter of 2025 CUPERTINO, Calif., August 12, 2025 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 DURECT CORPORATION (Name of Subject Company) DURECT CORPORATION

SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 DURECT CORPORATION (Name of Subject Company) DURECT CORPORATION (Name of Person(s) Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 266605500 (CUSIP Number of Clas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (C

Amendment No. 1 to the Agreement and Plan of Merger by and among DURECT Corporation, Bausch Health Americas, Inc., and BHC Lyon Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K, as filed with the SEC on August 8, 2025).

EX-2.1 Exhibit 2.1 AMENDMENT NO. 1 TO MERGER AGREEMENT This AMENDMENT NO. 1 TO MERGER AGREEMENT (this “Amendment”), dated as of August 8, 2025, is made by and among Bausch Health Americas, Inc., a Delaware corporation (“Parent”), BHC Lyon Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of Parent (“Merger Sub”), DURECT Corporation, a Delaware corporation (the “Company”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMPANIES INC. (Names of

Excerpted transcript of applicable “question and answer” portions of BHC’s Second-Quarter 2025 Earnings Presentation, dated July 30, 2025.

EX-99.1 Exhibit 99.1 The following are excerpts from the transcript of the “question and answer” portion of the Bausch Health Second-Quarter 2025 Earnings Presentation, held on Wednesday, July 30, 2025 from 5:00pm to 5:44 pm ET. * * * Douglas Miehm, Analyst, RBC Dominion Securities, Inc. – Question: Well, yeah, I did want to just ask on DURECT. Is there any additional information you can provide o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMPANIES INC. (Names of Filing

Excerpted transcript of applicable portions of BHC’s Second-Quarter 2025 Earnings Presentation, dated July 30, 2025.

Exhibit 99.1 The following are excerpts from the transcript of the Bausch Health Second-Quarter 2025 Earnings Presentation, held on Wednesday, July 30, 2025 at 5:00pm ET. * * * Tom Appio (Chief Executive Officer): We announced after the quarter that we entered into an agreement to acquire DURECT Corporation, which, if all closing conditions are satisfied and the acquisition closes, will enable Bau

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 28, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 28, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] 877-281-6642 (toll-free) (908) 569-3692 Investor Relations (DURECT Corporation) Media Contact (DURECT Corporation) Sandya von der Weid Michael Fitzhugh LifeSci Advisors LifeSci Communications [email protected] [email protected] Ba

Press Release, dated July 29, 2025.

EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] 877-281-6642 (toll-free) (908) 569-3692 Investor Relations (DURECT Corporation) Media Contact (DURECT Corporation) Sandya von der Weid Michael Fitzhugh LifeSci Advisors LifeSci Communications [email protected] [email protected] Ba

Form of Retention Plan

EX-10.1 Exhibit 10.1 Execution Version DURECT CORPORATION RETENTION PLAN Effective as of July 28, 2025 1. Purpose. The purpose of this Retention Plan is to reinforce and encourage the continued attention and dedication of certain key service providers of the Company by providing the opportunity for such key service providers to receive Retention Bonus payments over time in connection with the achi

Form of Contingent Value Rights Agreement, by and between Bausch Health Americas, Inc. and a rights agent mutually acceptable to Bausch Health Americas, Inc. and DURECT Corporation

EX-2.2 3 d50216dex22.htm EX-2.2 Exhibit 2.2 CONTINGENT VALUE RIGHTS AGREEMENT by and among BAUSCH HEALTH AMERICAS, INC. and [RIGHTS AGENT] Dated as of [⚫], 2025 TABLE OF CONTENTS Page ARTICLE 1. DEFINITIONS 2 Section 1.1. Defined Terms 2 Section 1.2. Additional Interpretations 5 ARTICLE 2. CONTINGENT VALUE RIGHTS 7 Section 2.1. CVRs 7 Section 2.2. CVR Register; Registration; Transferability 7 Sect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMPANIES INC. (Names of

DURECT Employee Q&A Agreement Between DURECT and Bausch

EX-99.1 Exhibit 99.1 DURECT Employee Q&A Agreement Between DURECT and Bausch 1) What has been announced? On July 28, 2025, DURECT and Bausch Health Companies Inc. (“Bausch”) jointly announced an agreement under which Bausch will acquire all outstanding shares of common stock of DURECT for $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million at closin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 DURECT CORPORATION (Name of Subject Company) DURECT CORPORATION

SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 DURECT CORPORATION (Name of Subject Company) DURECT CORPORATION (Name of Person(s) Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 266605500 (CUSIP Number of Clas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 DURECT CORPORATION (Name of Subject Company) DURECT CORPORATION

SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 DURECT CORPORATION (Name of Subject Company) DURECT CORPORATION (Name of Person(s) Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 266605500 (CUSIP Number of Clas

Agreement and Plan of Merger by and among Bausch Health Americas, Inc., BHC Lyon Merger Sub, Inc., DURECT Corporation, and solely for purposes of Section 6.10, Bausch Health Companies Inc.*

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among BAUSCH HEALTH AMERICAS, INC., BHC LYON MERGER SUB, INC., DURECT CORPORATION and BAUSCH HEALTH COMPANIES INC. solely for purposes of Section 6.10 Dated as of July 28, 2025 TABLE OF CONTENTS Page ARTICLE 1. DEFINITIONS 2 Section 1.1. Defined Terms 2 Section 1.2. Additional Interpretations 13 ARTICLE 2. THE OFFER 14 Section 2.1.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 9, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (E

DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initia

Exhibit 99.1 DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif., May 13, 2025 /PRNewswire /

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Com

Insider Trading Policy.

Exhibit 19.1 DURECT CORPORATION INSIDER TRADING POLICY (As Approved by the Board of Directors on December 13, 2024) This document sets forth the policy (this “Policy”) regarding trading in the stock and other securities of DURECT Corporation (the “Company”) and certain other publicly traded companies with which the Company has a business relationship while in possession of material non-public info

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-31615 DURECT CORPORA

Asset purchase agreement by and between the Company and ALZET, LLC dated as of November 22, 2024.

Exhibit 10.22 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [* * *], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version ASSET PURCHASE AGREEMENT BY AND BETWEEN DURECT CORPORATION AND ALZET, LLC November 22, 2024 TABLE OF CONTENTS Page Article I PURCHA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 26, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (C

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at Th

Exhibit 99.1 DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call toda

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company’s planned Phase 3 trial

Exhibit 99.1 DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company’s planned Phase 3 trial CUPERTINO, Calif., January 28, 2025 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed art

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 28, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 9, 2025 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 22, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organizatio

DURECT CORPORATION PRO FORMA CONDENSED BALANCE SHEETS AS OF SEPTEMBER 30, 2024 (in thousands)

Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION On November 22, 2024 (the “Closing Date”), DURECT Corporation (the “Company”) completed the sale (the “Transaction”) to Alzet, LLC, a subsidiary of Lafayette Instrument Co. (the “Purchaser”), of substantially all the assets and certain specified liabilities related to the ALZET product line (the “Sale”) pursuant to the Asset Purchase

DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million

Exhibit 99.1 DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million CUPERTINO, Calif. – Nov. 25, 2024 – DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 22, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

DRRX / DURECT Corporation / ASEN R SCOTT - SC 13G/A Passive Investment

SC 13G/A 1 tm2428914d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Durect Corp. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 266605500 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 DURECT CORPORATION (Exact name of Registrant as specified in its charter)

As filed with the Securities and Exchange Commission on November 14, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATIO

Filing Fee Exhibit.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) DURECT Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.

Amendment No. 1 to Exclusive License Agreement between the Company and Virginia Commonwealth University Intellectual Property Foundation dated July 2, 2015.

CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [* * *], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv).

Amendment No. 2 to Exclusive License Agreement between the Company and Virginia Commonwealth University Intellectual Property Foundation dated March 6, 2018.

CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [* * *], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv).

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company.

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DURECT CORPORATION The undersigned, James E. Brown, hereby certifies that: 1. He is the President and Chief Executive Officer of Durect Corporation, a Delaware corporation (the “Corporation”). 2. The original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 13, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update - Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call

Exhibit 99.1 DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update - Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., November 13, 2024 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 25, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization

DURECT Corporation 2000 Stock Plan, as amended

Exhibit 10.1 DURECT CORPORATION 2000 STOCK PLAN (as amended on March 13, 2000) (as further amended on March 31, 2000) (as further amended on March 15, 2001) (as further amended April 14, 2005) (as further amended June 23, 2010) (as further amended June 23, 2011) (as further amended June 16, 2014) (as further amended June 22, 2016) (as further amended June 19, 2018) (as further amended June 19, 201

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Si

Exhibit 99.1 DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 25, 2024 Date of Report (Date of earliest event reported) DURECT CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 25, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 25, 2024 Date of Report (Date of earliest event reported) DURECT CORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 25, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Si

Exhibit 99.1 DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two year

[Signature page follows]

August 20, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky, Office of Life Sciences Re: DURECT Corporation Registration Statement on Form S- Filed August 14, 2024 File No. 333-281550 REQUEST FOR ACCELERATION OF EFFECTIVENESS Acceleration Request Requested Date: August 23, 2024 Requested Time: 4:00

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) DURECT Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (Ex

Form of Indenture

Exhibit 4.15 DURECT CORPORATION AND              , as Trustee INDENTURE Dated as of           Debt Securities Reconciliation and tie between Trust Indenture Act of 1939, as amended, and the Indenture Trust Indenture Act Section Indenture Section §310(a)(1) 6.8 (a)(2) 6.8 (b) 6.9 §312(a) 7.1 (b) 7.2 (c) 7.2 §313(a) 7.3 (b)(2) 7.3 (c) 7.3 (d) 7.3 §314(a) 7.4 (c)(1) 1.2 (c)(2) 1.2 (e) 1.2 §316(a) (la

As filed with the Securities and Exchange Commission on August 14, 2024

Table of Contents As filed with the Securities and Exchange Commission on August 14, 2024 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 13, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (

DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Des

Exhibit 99.1 DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design - Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 - Webcast of Earnings Call Today, August 13th at

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 26, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

Form of Employee Restricted Stock Unit Award Agreement for use with the DURECT Corporation 2000 Stock Plan

Exhibit 10.1 DURECT CORPORATION 2000 STOCK PLAN NOTICE OF RESTRICTED STOCK UNIT GRANT Participant Name: [INSERT NAME] You have been granted the right to receive an Award of Restricted Stock Units (“RSUs”), subject to the terms and conditions of this Notice of Restricted Stock Unit Grant (the “Notice of Grant”), the attached Restricted Stock Unit Agreement (together with the Notice of Grant, the “A

Letter dated June 28, 2024 from Ernst & Young LLP to the U.S. Securities and Exchange Commission

Exhibit 16.1 June 28, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated June 28, 2024, of DURECT Corporation and are in agreement with the statements contained in paragraphs one through four therein under (a) Dismissal of Independent Registered Public Accounting Firm. We have no basis to agree or disagree with ot

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 28, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial

Exhibit 99.1 DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. – May 21, 2024 – DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Com

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET

Exhibit 99.1 DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif., May 13, 2024 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (C

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis

Exhibit 99.1 DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis CUPERTINO, Calif. – April 30, 2024 – DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such

Up to $12,400,000 Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-258333 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated August 16, 2021 and Prospectus dated August 16, 2021) Up to $12,400,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement dated August 16, 2021 (the “Initial Prospectus Supplement”). This prospectus supplement should be read in

Company Compensation Recovery Policy

Exhibit 97.1 durect corporation COMPENSATION RECOVERY POLICY (Adopted and approved on November 18, 2023 and effective as of October 2, 2023) 1. Purpose DURECT Corporation (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Compa

Description of Securities of the Registrant Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended.

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DURECT Corporation (“we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following summary of the terms of our common stock is based upon our Amended and Rest

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-31615 DURECT CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (C

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, Ma

Exhibit 99.1 DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif., March 27, 2024 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 22, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 22, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (C

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 4, 2024 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

Exhibit 99.1 DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada • Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada • Both companies will jointly market and commercialize the ALZET product line to

US2666055007 / Durect Corp / ASEN R SCOTT - SC 13G Passive Investment

SC 13G 1 tm246550d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Durect Corp. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 266605500 (CUSIP Number) February 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

US2666055007 / Durect Corp / Lion Point Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Durect Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 266605500 (CUSIP Number) December 31, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 22, 2023 (December 21, 2023) Date of Report (Date of earliest event report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 22, 2023 (December 21, 2023) Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporat

DRRX / Durect Corp / Bleichroeder LP - 13G/A Passive Investment

SC 13G/A 1 Durect13gFINAL.htm 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Durect Corporation (Name of Issuer) Common Shares (Title of Class of Securities) 266605104 (CUSIP Number) November 30, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATIO

Sixth amendment to Lease between the Company and De Anza Enterprises LLC dated as of September 6, 2023 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 000-31615), as filed with the SEC on November 14, 2023).

Exhibit 10.2 SIXTH AMENDMENT TO LEASE This Sixth Amendment to Lease (this “Sixth Amendment”) is made and entered into effective as of September 6, 2023, which is the date that this Sixth Amendment has been fully executed by all of those persons required to sign it (the “Effective Date”), by and between De Anza Enterprises LLC, a California limited liability company (“Landlord”), and DURECT Corpora

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update - Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET - Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the ke

Exhibit 99.1 DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update - Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET - Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days CUPERTINO, Calif., November 13, 2023 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 13, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 13, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortalit

Exhibit 99.1 DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days. Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg dose compared with standard of ca

Disclaimer This presentation and various remarks we make during this presentation contain forward-looking statements of DURECT Corporation ("DURECT," the "Company," "we," "our" or "us") and its collaborative partners within the meaning of applicable

Phase 2b AHFIRM Topline Results November 2023 Exhibit 99.2 Disclaimer This presentation and various remarks we make during this presentation contain forward-looking statements of DURECT Corporation ("DURECT," the "Company," "we," "our" or "us") and its collaborative partners within the meaning of applicable securities laws and regulations, which are subject to the safe harbor provisions of the Pri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 7, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 7, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Exhibit 99.1 DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif. – September 7, 2023 – DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of se

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 DURECT CORPORATION (Exact name of Registrant as specified in its charter)

As filed with the Securities and Exchange Commission on August 10, 2023 Registration No.

Filing Fee Exhibit.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) DURECT Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (Ex

Addendum IV to Lease between the Company and Wescove Vacaville, LLC dated as of May 11, 2023 (incorporated by reference Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 000-31615) filed with the SEC on August 10, 2023).

Exhibit 10.1 ADDENDUM IV TO STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - GROSS THIS ADDENDUM IV (“ADDENDUM IV”) is made and entered into as of the 11th day of May 2023 by and between WESCOVE VACAVILLE, LLC, a California Limited Liability Company (hereinafter referred to as “Lessor”), and DURECT CORPORATION, a Delaware Corporation (hereinafter referred to as “Lessee”); RECITALS WHEREAS, pred

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (C

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update - Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in Q4 2023

Exhibit 99.1 DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update - Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in Q4 2023 CUPERTINO, Calif., August 9, 2023 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate upda

2,991,027 Shares of Common Stock Common Warrants to Purchase up to 2,991,027 Shares of Common Stock DURECT CORPORATION

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258333 PROSPECTUS SUPPLEMENT (To Prospectus dated August 16, 2021) 2,991,027 Shares of Common Stock Common Warrants to Purchase up to 2,991,027 Shares of Common Stock DURECT CORPORATION We are offering 2,991,027 shares of our common stock and accompanying common warrants to purchase up to 2,991,027 shares of our common s

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

EX-99.1 Exhibit 99.1 DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules CUPERTINO, Calif., July 20, 2023 / PRNewswire / — DURECT Corporation (Nasdaq: DRRX) (“DURECT”), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 19, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 19, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

Securities Purchase Agreement, dated July 19, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on July 21, 2023).

EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 19, 2023, between DURECT Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio

Form of Warrant (July 2023) (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on July 21, 2023).

EX-4.1 Exhibit 4.1 EXHIBIT A-1 COMMON STOCK PURCHASE WARRANT DURECT CORPORATION Warrant Shares: Initial Exercise Date: , 2023 Issue Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 21, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

2000 Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 000-31615) filed on June 22, 2023).

Exhibit 10.1 DURECT CORPORATION 2000 EMPLOYEE STOCK PURCHASE PLAN (as last amended June 21, 2023) The following constitute the provisions of the 2000 Employee Stock Purchase Plan of DURECT Corporation, as amended and restated effective as of the Restatement Effective Date (as defined below). 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Subsidiaries

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 7, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 7, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Com

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis Topline data anticipated in Q4 2023

Exhibit 99.1 DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis Topline data anticipated in Q4 2023 CUPERTINO, Calif., June 7, 2023 — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic liver diseases, today announced that it has completed enrollment i

Key Opinion Leader Discussion:Larsucosterol &Alcohol-associated HepatitisMay 16th, 2023

Key Opinion Leader Discussion: Larsucosterol & Alcohol-associated Hepatitis May 16th, 2023 Agenda Introduction / Welcome Jim Brown, DVM What is AH? Paul Gaglio, MD Larsucosterol: Addressing the AH Treatment Gap Brett Fortune, MD Larsucosterol and the Phase 2b AHFIRM Trial Norman Sussman, MD Larsucosterol Commercial Opportunity Keith Lui Q&A 2 Disclaimer This presentation and various remarks we mak

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (E

DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update - Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in 2H 2023

Exhibit 99.1 DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update - Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in 2H 2023 CUPERTINO, Calif., May 8, 2023 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2023 and provided a corporate update. “W

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Comm

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis Data expands upon previously reported results, including individual patient

Exhibit 99.1 DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis Data expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study Company on track to report data from on

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 10, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 10, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (C

DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

Exhibit 99.1 DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board CUPERTINO, Calif., March 21, 2023 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023. Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 DURECT CORP (Exact name of Registrant as Specified in Its Charter) Delaware 000-31615 94-3297098 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (C

Amendment to Offer Letter between Judy Joice and DURECT Corporation dated March 31, 2014.

Exhibit 10.30 March 31, 2014 Judith Joice [PERSONAL CONTACT INFORMATION REDACTED] [PERSONAL CONTACT INFORMATION REDACTED] Dear Judy: In recognition of your excellent performance, hard work and dedication to DURECT, effective April 1, 2014 we would like to promote you to the position of Sr. Vice-President, Operations and Corporate Quality Assurance. With this promotion your annual salary will incre

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-31615 DURECT CORPORA

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.8 of the Company's Annual Report on Form 10-K, as filed with the SEC on March 8, 2023).

Exhibit 3.8 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DURECT CORPORATION The undersigned, James E. Brown, hereby certifies that: 1. He is the President and Chief Executive Officer of Durect Corporation, a Delaware corporation (the “Corporation”). 2. The original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on

Offer letter between Judy Joice and DURECT Corporation dated May 9, 2007.

Exhibit 10.29 May 9, 2007 Judith Joice [PERSONAL CONTACT INFORMATION REDACTED] [PERSONAL CONTACT INFORMATION REDACTED] Dear Judy: It is a pleasure to confirm the offer extended to you to join DURECT Corporation as Executive Director, Quality Assurance reporting into me. As an exempt, full-time, regular employee, your starting base salary will be $8,333.33 on a semi-monthly basis, which equates to

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DURECT Corporation (“we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following summary of the terms of our common stock is based upon our Amended and Rest

DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update - - Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET - - Topline data from AHFIRM trial expected in 2023

Exhibit 99.1 DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update - - Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET - - Topline data from AHFIRM trial expected in 2023 CUPERTINO, Calif., March 7, 2023 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 7, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 7, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

DRRX / DURECT Corporation / Bleichroeder LP - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Durect Corporation (Name of Issuer) Common Shares (Title of Class of Securities) 266605104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

DRRX / DURECT Corporation / Lion Point Capital, LP Passive Investment

SC 13G/A 1 durectsc13ga1-021423.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Durect Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 266

DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants

EX-99.1 Exhibit 99.1 DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants CUPERTINO, Calif., February 3, 2023 / PRNewswire / — DURECT Corporation (Nasdaq: DRRX) (“DURECT”), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has ente

Form of Pre-Funded Warrant (February 2023) (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, as filed with the SEC on February 7, 2023).

EX-4.2 Exhibit 4.2 [FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT] DURECT CORPORATION Warrant Shares: Issue Date: February [], 2023 Initial Exercise Date: February [], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herein

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 3, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 3, 2023 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

1,700,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 300,000 Shares of Common Stock Common Warrants to Purchase up to 2,000,000 Shares of Common Stock DURECT CORPORATION

424B5 1 d442719d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258333 PROSPECTUS SUPPLEMENT (To Prospectus dated August 16, 2021) 1,700,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 300,000 Shares of Common Stock Common Warrants to Purchase up to 2,000,000 Shares of Common Stock DURECT CORPORATION We are offering 1,700,000 shares of our c

Form of Securities Purchase Agreement, dated February 3, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on February 7, 2023).

EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 3, 2023, between DURECT Corporation, a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement an

Form of Warrant (February 2023) (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on February 7, 2023).

EX-4.1 Exhibit 4.1 [FORM OF COMMON STOCK PURCHASE WARRANT] DURECT CORPORATION Warrant Shares: Issue Date: February [], 2023 Initial Exercise Date: February [], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 DURECT CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

Disclaimer This presentation and various remarks we make during this presentation contain forward-looking statements of DURECT Corporation ("DURECT," the "Company," "we," "our" or "us") and its collaborative partners within the meaning of applicable

EX-99.1 2 d408188dex991.htm EX-99.1 Unlocking Epigenetic Therapeutics to Revolutionize Medicine February 2023 Exhibit 99.1 Disclaimer This presentation and various remarks we make during this presentation contain forward-looking statements of DURECT Corporation ("DURECT," the "Company," "we," "our" or "us") and its collaborative partners within the meaning of applicable securities laws and regulat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 20, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 20, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 28, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

DURECT Announces 1-for-10 Reverse Stock Split

Exhibit 99.1 DURECT Announces 1-for-10 Reverse Stock Split CUPERTINO, Calif., November 28, 2022/PRNewswire/ - DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT?s board of directors today determined that the Company will effect a reverse stock sp

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 22, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATIO

First Amendment to License Agreement by and between the Company and Innocoll Pharmaceuticals Limited dated September 19, 2022 (incorporated by reference Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 000-31615) filed with the SEC on November 3, 2022).

Exhibit 10.1 FIRST AMENDMENT TO LICENSE AGREEMENT This First Amendment (this ?Amendment?) is entered into as of September 19, 2022 (the ?Amendment Effective Date?) between Innocoll Pharmaceuticals Ltd. (?INNOCOLL?) and DURECT Corporation (?DURECT?). RECITALS A. DURECT and INNOCOLL are parties to a License Agreement dated December 21, 2021 (the ?Agreement?); B. Pursuant to the Agreement, among othe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs - Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET - AHFIRM trial timeline continues to improve

Exhibit 99.1 DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs - Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET - AHFIRM trial timeline continues to improve CUPERTINO, Calif., November 2, 2022 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate u

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial AHFIRM enrollment surpasses 200 of the planned 300 AH patients Enrollment completion now anticipated in Q2 2023

Exhibit 99.1 DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial AHFIRM enrollment surpasses 200 of the planned 300 AH patients Enrollment completion now anticipated in Q2 2023 CUPERTINO, Calif., October 6, 2022/PRNewswire/ - DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chroni

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 6, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 26, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization

Innocoll and DURECT Announce U.S. launch of POSIMIR®

Exhibit 99.1 Innocoll and DURECT Announce U.S. launch of POSIMIR? - POSIMIR? is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery - DURECT recently received an $8 million milestone payment for a new patent issuance and has now earned a $2 million milestone payment for first commercial sale of POSIMIR AT

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (C

Filing Fee Exhibit.

EX-FILING FEES 4 drrx-exfilingfees6.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) DURECT Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 DURECT CORPORATION (Exact name of Registrant as specified in its charter)

As filed with the Securities and Exchange Commission on August 5, 2022 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 4, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (C

DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs -Webcast of Earnings Call Today, August 4th at 4:30 p.m. ET -Enrollment accelerating in the AHFIRM trial

Exhibit 99.1 DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs -Webcast of Earnings Call Today, August 4th at 4:30 p.m. ET -Enrollment accelerating in the AHFIRM trial CUPERTINO, Calif., August 4, 2022 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2022 and provided a corporate update. ?W

Offer letter between Timothy M. Papp and the Company (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on July 5, 2022).

Exhibit 10.1 June 17, 2022 Timothy M. Papp [PERSONAL CONTACT INFORMATION REDACTED] [PERSONAL CONTACT INFORMATION REDACTED] Via electronic delivery Dear Timothy: It is a pleasure to confirm the offer extended to you to join DURECT Corporation, located at 10260 Bubb Road, Cupertino, California, 95014, as Chief Financial Officer, reporting directly to me. We would like your start date to be July 1, 2

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

Exhibit 99.1 DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer CUPERTINO, Calif., July 5, 2022 - DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp wil

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 5, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Com

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on June 16, 2022).

EX-3.1 2 drrx-ex316.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DURECT CORPORATION The undersigned, James E. Brown, hereby certifies that: 1. He is the President and Chief Executive Officer of Durect Corporation, a Delaware corporation (the “Corporation”). 2. The original Certificate of Incorporation was filed with the Secretary of St

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 15, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

2000 Stock Plan, as amended (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on June 16, 2022).

Exhibit 10.1 DURECT CORPORATION 2000 STOCK PLAN (as amended on March 13, 2000) (as further amended on March 31, 2000) (as further amended on March 15, 2001) (as further amended April 14, 2005) (as further amended June 23, 2010) (as further amended June 23, 2011) (as further amended June 16, 2014) (as further amended June 22, 2016) (as further amended June 19, 2018) (as further amended June 19, 201

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (E

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Comm

DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs

Exhibit 99.1 DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs - Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET - Adding new clinical sites and patient dosing progressing in the AHFIRM trial CUPERTINO, Calif., May 4, 2022 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2022 and pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Fourth Amendment to Loan and Security Agreement between the Company and Oxford Finance LLC dated March 3, 2021 (incorporated by reference to Exhibit 10.26 to the Company’s Annual Report on Form 10-K (File No. 000-31615), as filed with the SEC on March 8, 2022).

Exhibit 10.26 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of March 3, 2021 (the ?Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacit

License agreement by and between the Company and Innocoll Pharmaceuticals Limited dated December 21, 2021 (incorporated by reference to Exhibit 10.28 to the Company’s Annual Report on Form 10-K (File No. 000-31615), as filed with the SEC on March 8, 2022).

Exhibit 10.28 Certain information identified by bracketed asterisks ([***]) has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. The omitted information will be filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted inform

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-31615 DURECT CORPORA

DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs

Exhibit 99.1 DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs - Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET - Dosed first patient in Europe in the AHFIRM trial - Signed a licensing agreement for POSIMIR? for up to $136M CUPERTINO, Calif., Mar. 7, 2022 /PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial resul

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 7, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 3, 2022 (February 25, 2022) Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 1, 2022 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis

Exhibit 99.1 DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis CUPERTINO, Calif., March 1, 2022/PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to ev

DRRX / DURECT Corporation / Lion Point Capital, LP - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Durect Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 266605104 (CUSIP Number) December 31, 2

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 11, 2022 (February 9, 2022) Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporati

DRRX / DURECT Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Durect Corp. Title of Class of Securities: Common Stock CUSIP Number: 266605104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 1

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

Exhibit 99.1 DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR? (Bupivacaine Solution) - DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and tiered low to mid double-digit royalties based on U.S. sales - - Innocoll granted exclusive development and commercialization rights to POSIMIR

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 22, 2021 (December 21, 2021) Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 14, 2021 (December 13, 2021) Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporat

DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia

Exhibit 99.1 DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia CUPERTINO, Calif., December 14, 2021/PRNewswire/ - DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter Garc?a, a biopharmaceutical industry veteran with over 25 years of financial leadership experi

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 12, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.

Exhibit 99.1 Data Presentation Today at The Liver Meeting? 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S. AH hospitalizations increased by approximately 4.8% per year between 2015 and 2018 Approximately 80% of AH patients who died while hospitalized had acute kidney failure CUPERTINO, Calif., November 12, 2021 /PRNewswire/ - DURECT Corporation (Nasdaq:

DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis

Exhibit 99.1 DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis CUPERTINO, Calif., November 10, 2021/PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first ex-U.S. patient in Australia as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

Amendment No. 2 to Exclusive License Agreement between the Company and Virginia Commonwealth University Intellectual Property Foundation dated March 6, 2018.

Exhibit 10.2 Certain information identified by bracketed asterisks ([***]) has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted information. AMENDMENT NO. 2 TO EXCLUSIVE LICENSE AGREEMENT THIS AMENDMENT No. 2 TO EXCLUSIVE LICENSE AGREEMENT is entered into on March 6, 2018 (the ?Effective Date of the

Amendment No. 1 to Exclusive License Agreement between the Company and Virginia Commonwealth University Intellectual Property Foundation dated July 2, 2015.

Exhibit 10.1 Certain information identified by bracketed asterisks ([***]) has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted information. AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT THIS AMENDMENT No. 1 TO EXCLUSIVE LICENSE AGREEMENT is entered into on July 2, 2015 (the ?Effective Date of the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATIO

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs -Earnings Call and Webcast Today, November 2nd at 4:30 p.m. ET -Expanded number of AHFIRM study sites -Opened first ex-US AHFIRM study sites -Advanced POSIMIR lice

Exhibit 99.1 DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs -Earnings Call and Webcast Today, November 2nd at 4:30 p.m. ET -Expanded number of AHFIRM study sites -Opened first ex-US AHFIRM study sites -Advanced POSIMIR licensing process CUPERTINO, Calif., November 2, 2021/PRNewswire/ - DURECT Corporation (Nasdaq: DRRX) today announced financial results for t

[Signature page follows]

August 12, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christine Westbrook, Office of Life Sciences Re: DURECT Corporation Registration Statement on Form S-3 Filed July 30, 2021 File No. 333-258333 REQUEST FOR ACCELERATION OF EFFECTIVENESS Acceleration Request Requested Date: August 16, 2021 Requested Time:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (Ex

Controlled Equity OfferingSM Sales Agreement dated as of July 30, 2021, by and between the Company and Cantor Fitzgerald & Co.

EX-1.4 2 drrx-ex14178.htm EX-1.4 Exhibit 1.4 DURECT Corporation Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement July 30, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: DURECT Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”

As filed with the Securities and Exchange Commission on July 30, 2021

As filed with the Securities and Exchange Commission on July 30, 2021 Registration No.

Form of Indenture

EX-4.6 3 drrx-ex46139.htm EX-4.6 Exhibit 4.6 DURECT CORPORATION AND , as Trustee, INDENTURE Dated as of Debt Securities Reconciliation and tie between Trust Indenture Act of 1939, as amended, and the Indenture Trust Indenture Act Section Indenture Section (S)310(a)(1) 6.8 (a)(2) 6.8 (b) 6.9 (S)312(a) 7.1 (b) 7.2 (c) 7.2 (S)313(a) 7.3 (b)(2) 7.3 (c) 7.3 (d) 7.3 (S)314(a) 7.4 (c)(1) 1.2 (c)(2) 1.2 (

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs Earnings Call and Webcast Today, July 29th at 4:30 p.m. ET

EX-99.1 2 drrx-ex9916.htm EX-99.1 Exhibit 99.1 DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs Earnings Call and Webcast Today, July 29th at 4:30 p.m. ET CUPERTINO, Calif., July 29, 2021/PRNewswire/ - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update. Q2 2021 Accompl

Certificate of Correction to the Charter Amendment of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K/A, as filed with the SEC on June 25, 2021).

Exhibit 3.1 CERTIFICATE OF CORRECTION OF CERTIFICATE OF AMENDMENT OF DURECT CORPORATION DURECT Corporation, a Delaware corporation (the ?Corporation?), does hereby certify, pursuant to Section 103 of the Delaware General Corporation Law (the ?DGCL?): First: On June 15, 2021, the Corporation filed a Certificate of Amendment (the ?Certificate of Amendment?) of the Corporation?s Amended and Restated

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 23, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL) New Data Further Supports DUR-928’s Potential in Acute and Chronic as w

EX-99.1 2 drrx-ex9916.htm EX-99.1 Exhibit 99.1 DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL) New Data Further Supports DUR-928’s Potential in Acute and Chronic as well as Moderate and Severe Liver Disease CUPERTINO, Calif., June 23, 2021, - DURECT Corporation (Nasdaq

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on June 16, 2021).

EX-3.1 2 drrx-ex316.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DURECT CORPORATION The undersigned, James E. Brown, hereby certifies that: 1. He is the President and Chief Executive Officer of Durect Corporation, a Delaware corporation (the “Corporation”). 2. The original Certificate of Incorporation was filed with the Secretary of St

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 15, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Com

Fifth Amendment to Loan and Security Agreement between the Company and Oxford Finance LLC dated May 28, 2021 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on June 2, 2021).

EX-10.1 2 drrx-ex1016.htm EX-10.1 Exhibit 10.1 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of May 28, 2021, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (E

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Comm

DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET

Exhibit 99.1 DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET CUPERTINO, Calif., May 4, 2021/PRNewswire/ - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2021 and provided a corporate update. Q1 2021 Accomplishments: ? Initiated patient dosing in

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

- PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 9, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

DURECT Corporation Announces Publication of DUR-928’s Mechanism of Action -- DUR-928 is an inhibitor of DNA methyltransferases (DNMTs) regulating expression of genes involved in cell survival, inflammation and lipid biosynthesis -- Mechanism of actio

Exhibit 99.1 DURECT Corporation Announces Publication of DUR-928’s Mechanism of Action - DUR-928 is an inhibitor of DNA methyltransferases (DNMTs) regulating expression of genes involved in cell survival, inflammation and lipid biosynthesis - Mechanism of action supports development of DUR-928 for the treatment of multiple acute organ injury and chronic diseases - Published in peer reviewed Journa

Webcast of Earnings Call Today, March 4th at 4:30 p.m. Eastern Time

Exhibit 99.1 DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs Webcast of Earnings Call Today, March 4th at 4:30 p.m. Eastern Time CUPERTINO, Calif., March 4, 2021/PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2020 and provided a corporate update. “We have ach

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 4, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (

Executive Change of Control Policy, as amended December 9, 2020 (incorporated by reference to Exhibit 10.33 to the Company’s Annual Report on Form 10-K (File No. 000-31615), as filed with the SEC on March 5, 2021)

EX-10.33 3 drrx-ex1033588.htm EX-10.33 Exhibit 10.33 DURECT CORPORATION EXECUTIVE CHANGE OF CONTROL POLICY (As Approved by the Board of Directors on December 9, 2020) This Executive Change of Control Policy (the “Policy”) is effective as of April 7, 2004, as amended on September 25, 2008, December 12, 2013 and December 9, 2020. POLICY GOALS A.It is expected that the Company from time to time will

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-31615 DURECT CORPORA

Asset purchase agreement between the Company and Evonik Corporation dated December 4, 2020.

EX-10.32 2 drrx-ex1032586.htm EX-10.32 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Execution Version Exhibit 10.32 ASSET PURCHASE AGREEMENT by and between DURECT CORPORATION and EVONIK CORPORATION As of December 4, 20

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 4, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization) (Co

Webcast of Earnings Call Today, March 4th at 4:30 p.m. Eastern Time

EX-99.1 2 drrx-ex9916.htm EX-99.1 Exhibit 99.1 DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs Webcast of Earnings Call Today, March 4th at 4:30 p.m. Eastern Time CUPERTINO, Calif., March 4, 2021/PRNewswire / - DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2020 and provide

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Durect Corporation (Name of Issuer) Common Shares (Title of Class of Securities) (CUSIP Number) December

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Durect Corporation (Name of Issuer) Common Shares (Title of Class of Securities) 266605104 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Durect Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 266605104 (CUSIP Number) December 31, 2

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Durect Corp. Title of Class of Securities: Common Stock CUSIP Number: 266605104 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1

DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock

EX-99.1 4 d108076dex991.htm EX-99.1 Exhibit 99.1 DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock CUPERTINO, Calif., February 4, 2021 / PRNewswire / — DURECT Corporation (Nasdaq: DRRX) (“DURECT”), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving the

Underwriting Agreement, dated February 3, 2021, by and between DURECT Corporation and Cantor Fitzgerald & Co.

EX-1.1 Exhibit 1.1 DURECT Corporation 17,708,333 Shares of Common Stock (par value $0.0001 per share) Underwriting Agreement February 3, 2021 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: DURECT Corporation, a Delaware corporation (the “Company”), proposes to iss

17,708,333 Shares DURECT CORPORATION Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-226518 PROSPECTUS SUPPLEMENT (To Prospectus dated October 9, 2018) 17,708,333 Shares DURECT CORPORATION Common Stock We are offering 17,708,333 shares of our common stock. Our common stock is quoted on The Nasdaq Capital Market under the symbol “DRRX.” On February 3, 2021, the last reported sales price of our common stoc

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2021 DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

Results of Operations and Financial Condition, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2021 DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)

SUBJECT TO COMPLETION, DATED FEBRUARY 3, 2021

424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.

DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression POSIMIR is the only approved sustained-release bupivacaine product indicated for up to 72

Exhibit 99.1 DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression POSIMIR is the only approved sustained-release bupivacaine product indicated for up to 72 hours of post-surgical analgesia from a single application Conference Call Today, February 2, 2021 at 4:30pm ET CUPERTINO, Calif., Februa

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 2, 2021 Date of Report (Date of earliest event reported) DURECT CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-31615 94-3297098 (State or other jurisdiction of incorporation or organization)